Table 4 Human Telomerase Reverse Transcriptase Clinical Trials
Clinical Trials | Vaccine Type | Cancer type | HLA | Immune monitoring | Responding patients | Ref. |
|---|---|---|---|---|---|---|
Phase 1 | Renal tumor mRNA transfected DCs | Metastatic renal carcinoma (stage IV) | No restriction | ELISPOT, 51Cr-assay | 6/7 (86%) | [45] |
Phase 1 | p540 in IFA | Metastatic Cancer (Renal, melanoma, colon) | HLA-A2+ | Tetramer staining, IFNγ secretion | 7/14 (50%) | [46] |
Phase 1 | p540 in KLH DCs | Hormone-independent prostate Cancer | HLA-A2+ | Tetramer staining, ELISPOT, Ag-specific lymphocyte proliferation assay | 2/5 (40%) | [47] |
| Â | Â | Metastatic breast cancer | HLA-A2+ | Â | 2/2 (100%) | Â |
Phase 1 | Autologous transgenic B lymphocyes (p540 and pY572) | Androgen-Independent prostate cancer | HLA-A2+ | Tetramer staining, Expansion of peptide-reactive CTL, 51Cr-assay | 10/15 (67%) | [51] |
Phase 1 | hTRT mRNA-transfected DCs | Metastatic prostate cancer | No restriction | ELISPOT, 51Cr-assay, Ag-specific proliferation assay | 8/9 (89%) | [50] |
Phase 1 | p540, p613 (HLA-DR, -DQ -DP) and GM-CSF | Non-small cell lung cancer | No restriction | 51Cr-assay, lymphocyte proliferation assay | 11/24 (46%) response to p611 | [48] |
| Â | Â | Â | No restriction | Â | 2/24 (8%) response to p540 | Â |